Coronary artery diseasePlasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction
Section snippets
Patients
This case-control study examined 879 patients who underwent angiographic examination and coronary stenting due to significant CAD from August 2001 to February 2002 in the Deutsches Herzzentrum (Munich, Germany). A consecutive series of 684 patients who had angiographically proved significant CAD (385 patients who had stable angina, 108 who had unstable angina, and 191 who had AMI) formed the patient group. The control group consisted of 195 subjects who had normal coronary artery angiograms
Characteristics of patients and controls
Distribution of the main cardiovascular risk factors among patients and controls is presented in Table 1. As expected, patients versus control subjects had a more adverse cardiovascular risk profile. Patients were older and there were fewer women compared with control subjects. Diabetes, arterial hypertension, and hypercholesterolemia were encountered in a larger proportion of patients than of controls. Higher levels of C-reactive protein and of creatinine were found in patients compared with
Discussion
This study indicates that concentrations of NT–pro-BNP are increased across the entire spectrum of clinical CAD. Further, data from this study demonstrate, in a consecutive series of patients who had CAD, that the level of NT–pro-BNP parallels the severity of myocardial ischemia. On a median basis, patients who had stable angina, those who had unstable angina, and those who had AMI showed increases of 2.8-, 5.6-, and 8.9-fold in concentrations of NT–pro-BNP compared with control subjects who
References (28)
- et al.
B-type natriuretic peptide in cardiovascular disease
Lancet
(2003) - et al.
Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting
J Am Coll Cardiol
(2001) - et al.
Increased plasma levels of B-type natriuretic peptide in patients with unstable angina
Am Heart J
(1996) - et al.
Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction
Am J Cardiol
(1995) - et al.
N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation
J Am Coll Cardiol
(2002) - et al.
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease
J Am Coll Cardiol
(2003) - et al.
Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length
Circulation
(2000) - et al.
Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
Circulation
(1993) - et al.
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
Circulation
(1994) - et al.
Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure
J Clin Endocrinol Metab
(1993)
Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment
Heart
Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina
Heart
Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction
Circulation
Relationship between plasma level of brain natriuretic peptide and myocardial infarct size
Cardiology
Cited by (65)
NT-pro-BNP: A novel predictor of stroke risk after transient ischemic attack
2020, International Journal of Cardiology